MCID: MCR088
MIFTS: 58

Microscopic Polyangiitis

Categories: Rare diseases, Neuronal diseases, Cardiovascular diseases, Nephrological diseases, Respiratory diseases, Bone diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 49 55 36
Microscopic Polyarteritis 55 69
Micropolyangiitis 55
Mpa 55

Characteristics:

Orphanet epidemiological data:

55
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:



Summaries for Microscopic Polyangiitis

NIH Rare Diseases : 49 Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown. Last updated: 8/13/2014

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to anca-associated vasculitis and churg-strauss syndrome, and has symptoms including renal insufficiency, sinusitis and epistaxis. An important gene associated with Microscopic Polyangiitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Methotrexate and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and neutrophil.

Wikipedia : 72 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 283)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 32.5 HLA-DRB1 MPO
2 churg-strauss syndrome 30.3 IL10 MPO TNF
3 wegener granulomatosis 30.3 IL10 MPO TNF
4 endocarditis 29.9 IL10 TNF
5 prostatitis 29.9 IL10 TNF
6 central nervous system vasculitis 29.8 HLA-DRB1 TNF
7 lung disease 29.7 IL10 MPO TNF
8 pneumonia 29.5 IL10 MPO TNF
9 chlamydia 29.5 IL10 TNF
10 gastrointestinal system disease 29.3 IL10 MPO TNF
11 mixed connective tissue disease 29.3 HLA-DRB1 IL10 TNF
12 connective tissue disease 29.3 HLA-DRB1 IL10 TNF
13 arthritis 29.2 HLA-DRB1 IL10 TNF
14 takayasu arteritis 29.2 HLA-B HLA-DRB1 TNF
15 cytomegalovirus infection 28.9 IL10 KIR3DL1 TNF
16 graft-versus-host disease 28.8 HLA-B HLA-DRB1 IL10 TNF
17 asthma 28.8 HLA-DRB1 IL10 MPO TNF
18 systemic lupus erythematosus 28.8 HLA-DRB1 IL10 MPO TNF
19 rheumatoid arthritis 28.6 HLA-B HLA-DRB1 IL10 TNF
20 vasculitis 11.4
21 polyarteritis nodosa, childhood-onset 10.4
22 polyarteritis nodosa 10.4
23 autoimmune inner ear disease 10.3 MPO TNF
24 juvenile myasthenia gravis 10.3 HLA-DRB1 IL10
25 granulocytopenia 10.3 MPO TNF
26 beryllium disease 10.3 HLA-DRB1 TNF
27 chronic beryllium disease 10.3 HLA-DRB1 TNF
28 autoimmune pancreatitis 10.3 HLA-DRB1 TNF
29 proctitis 10.3 MPO TNF
30 pleural disease 10.3 MPO TNF
31 lichen sclerosus 10.3 HLA-DRB1 TNF
32 fibrosis of extraocular muscles, congenital, 1 10.3
33 acute disseminated encephalomyelitis 10.2 HLA-DRB1 IL10
34 actinic prurigo 10.2 HLA-DRB1 TNF
35 sympathetic ophthalmia 10.2 HLA-DRB1 TNF
36 ileitis 10.2 MPO TNF
37 microscopic colitis 10.2 HLA-DRB1 TNF
38 suppurative cholangitis 10.2 MPO TNF
39 rheumatoid vasculitis 10.2 HLA-DRB1 TNF
40 discoid lupus erythematosus 10.2 HLA-DRB1 IL10
41 pleurisy 10.2 MPO TNF
42 cystic echinococcosis 10.2 HLA-DRB1 IL10
43 peanut allergy 10.2 HLA-DRB1 IL10
44 oligoarticular juvenile idiopathic arthritis 10.2 HLA-DRB1 TNF
45 punctate inner choroidopathy 10.2 IL10 TNF
46 tropical endomyocardial fibrosis 10.2 IL10 TNF
47 multifocal choroiditis 10.2 IL10 TNF
48 palindromic rheumatism 10.2 HLA-DRB1 TNF
49 tungiasis 10.2 IL10 TNF
50 dengue shock syndrome 10.2 HLA-DRB1 TNF

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

55 31 (show all 37)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 55 31 hallmark (90%) Very frequent (99-80%) HP:0000083
2 sinusitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000246
3 epistaxis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000421
4 uveitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000554
5 hematuria 55 31 hallmark (90%) Very frequent (99-80%) HP:0000790
6 cutis marmorata 55 31 occasional (7.5%) Occasional (29-5%) HP:0000965
7 skin rash 55 31 hallmark (90%) Very frequent (99-80%) HP:0000988
8 arthritis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001369
9 subcutaneous nodule 55 31 occasional (7.5%) Occasional (29-5%) HP:0001482
10 congestive heart failure 55 31 occasional (7.5%) Occasional (29-5%) HP:0001635
11 pericarditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001701
12 pancreatitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001733
13 subcutaneous hemorrhage 55 31 frequent (33%) Frequent (79-30%) HP:0001933
14 fever 55 31 hallmark (90%) Very frequent (99-80%) HP:0001945
15 diarrhea 55 31 frequent (33%) Frequent (79-30%) HP:0002014
16 nausea and vomiting 55 31 frequent (33%) Frequent (79-30%) HP:0002017
17 abdominal pain 55 31 frequent (33%) Frequent (79-30%) HP:0002027
18 hemoptysis 55 31 hallmark (90%) Very frequent (99-80%) HP:0002105
19 gastrointestinal hemorrhage 55 31 frequent (33%) Frequent (79-30%) HP:0002239
20 peritonitis 55 31 frequent (33%) Frequent (79-30%) HP:0002586
21 vasculitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0002633
22 arthralgia 55 31 frequent (33%) Frequent (79-30%) HP:0002829
23 autoimmunity 55 31 hallmark (90%) Very frequent (99-80%) HP:0002960
24 myalgia 55 31 frequent (33%) Frequent (79-30%) HP:0003326
25 paresthesia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003401
26 venous thrombosis 55 31 frequent (33%) Frequent (79-30%) HP:0004936
27 gastrointestinal infarctions 55 31 frequent (33%) Frequent (79-30%) HP:0005244
28 abnormality of the retinal vasculature 55 31 occasional (7.5%) Occasional (29-5%) HP:0008046
29 erythema 55 31 hallmark (90%) Very frequent (99-80%) HP:0010783
30 arrhythmia 55 31 occasional (7.5%) Occasional (29-5%) HP:0011675
31 oliguria 55 31 hallmark (90%) Very frequent (99-80%) HP:0100520
32 episcleritis 55 31 occasional (7.5%) Occasional (29-5%) HP:0100534
33 gangrene 55 31 occasional (7.5%) Occasional (29-5%) HP:0100758
34 glomerulopathy 55 31 hallmark (90%) Very frequent (99-80%) HP:0100820
35 skin ulcer 55 31 frequent (33%) Frequent (79-30%) HP:0200042
36 peripheral neuropathy 55 Occasional (29-5%)
37 increased inflammatory response 55 Very frequent (99-80%)

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
4
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
5
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
6
alemtuzumab Approved, Investigational Phase 4 216503-57-0
7
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
9
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
10
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
11
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
13 Alkylating Agents Phase 4,Phase 3,Phase 2
14 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
15 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
16 Dermatologic Agents Phase 4,Phase 3,Phase 2
17 Vitamin B Complex Phase 4,Phase 3,Phase 2
18 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
21 Antimetabolites Phase 4,Phase 3,Phase 2
22 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
23 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2
25 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Prednisolone acetate Phase 4,Phase 2,Phase 3
27 glucocorticoids Phase 4,Phase 2,Phase 3
28 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
29 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
30 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
31 Neuroprotective Agents Phase 4,Phase 2,Phase 3
32 Hormone Antagonists Phase 4,Phase 2,Phase 3
33 Hormones Phase 4,Phase 2,Phase 3
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
35 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
36 Antiemetics Phase 4,Phase 2,Phase 3
37 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3
38 Prednisolone phosphate Phase 4,Phase 2,Phase 3
39 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
40 Protective Agents Phase 4,Phase 2,Phase 3
41 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
42 Autonomic Agents Phase 4,Phase 2,Phase 3
43 Tin Fluorides Phase 4
44 Folate Nutraceutical Phase 4,Phase 3,Phase 2
45 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2
46
belimumab Approved Phase 3 356547-88-1 5957 10451420
47 Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1
48 Immunoglobulins Phase 3,Phase 2
49 Antibodies Phase 3,Phase 2
50 Antibodies, Antineutrophil Cytoplasmic Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 52)

# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
4 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
5 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Active, not recruiting NCT02169219 Phase 4 Glucocorticoids;Rituximab
6 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Suspended NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
7 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
8 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
9 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
10 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
11 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
12 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
13 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
14 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
15 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Active, not recruiting NCT00987389 Phase 3 Glucocorticoids
16 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
17 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
18 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
19 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
20 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
21 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
22 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
23 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
24 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Active, not recruiting NCT01750697 Phase 2 Rituximab
25 Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies Not yet recruiting NCT03385668 Phase 2 Pirfenidone
26 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
27 BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
28 CellCept in p-ANCA Vasculitis Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
29 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
30 Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
31 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
32 An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01613599 Rituximab
33 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Infliximab;Rituximab
34 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
35 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
36 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
37 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
38 Impact of Vasculitis on Employment and Income Completed NCT02476292
39 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
40 Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis Recruiting NCT00315393
41 Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis Recruiting NCT02474888
42 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Recruiting NCT01066208
43 Pediatric Vasculitis Initiative Recruiting NCT02006134
44 One-Time DNA Study for Vasculitis Recruiting NCT01241305
45 Journey of Patients With Vasculitis From First Symptom to Diagnosis Recruiting NCT03410290
46 VCRC Tissue Repository Recruiting NCT02967068
47 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
48 Vasculitis Pregnancy Registry Recruiting NCT02593565
49 Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Active, not recruiting NCT01862068
50 VCRC Patient Contact Registry Patient-Reported Data Validation Study Enrolling by invitation NCT02190942

Search NIH Clinical Center for Microscopic Polyangiitis

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

38
Skin, Lung, Neutrophil, Kidney, Bone, Heart, Liver

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 410)
# Title Authors Year
1
Frequency, Diagnosis, Treatment, and Outcome of Gastrointestinal Disease in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. ( 29419474 )
2018
2
From fibrosis to diagnosis: a paediatric case of microscopic polyangiitis and review of the literature. ( 29294176 )
2018
3
Necrosis of the gastrocnemius muscle in microscopic polyangiitis. ( 29374653 )
2018
4
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. ( 28733791 )
2017
5
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? ( 29165307 )
2017
6
Gallbladder bleeding associated with microscopic polyangiitis: a case report. ( 28852465 )
2017
7
Microscopic polyangiitis: Atypical presentation with extensive small bowel necrosis, diffuse alveolar hemorrhage, and renal failure. ( 28348948 )
2017
8
The effect and possible clinical efficacy of in vivo inhibition of neutrophil extracellular traps by blockade of PI3K-gamma on the pathogenesis of microscopic polyangiitis. ( 28880680 )
2017
9
A case of inclusion body myositis complicated by microscopic polyangiitis. ( 28726537 )
2017
10
Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. ( 28905856 )
2017
11
Phlebectasia in a finger in a case of microscopic polyangiitis with peripheral polyneuropathy. ( 28838824 )
2017
12
Microscopic polyangiitis with dermatomyositis. ( 29308288 )
2017
13
Concurrent Double Fungal Infections of the Skin Caused by Phialemoniopsis endophytica and Exophiala jeanselmei in a Patient with Microscopic Polyangiitis. ( 28654130 )
2017
14
Elevated serum levels of immunoglobulin A correlate with the possibility of readmission in patients with microscopic polyangiitis. ( 28616269 )
2017
15
Noninfective endocarditis in microscopic polyangiitis: Report of a case with a successful response to immunosuppressive therapy. ( 28822626 )
2017
16
Differential Expression of Toll-Like Receptor Signaling Pathway Is Associated with Microscopic Polyangiitis in Peripheral Blood Neutrophils. ( 28375762 )
2017
17
A Case of Microscopic Polyangiitis with Subarachnoid Hemorrhage and Cardiovascular Complications. ( 29142188 )
2017
18
Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. ( 29082297 )
2017
19
Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. ( 28539536 )
2017
20
A tale of two vasculitides: biopsy-proven giant cell arteritis followed by the independent development of renal-limited microscopic polyangiitis. ( 28432167 )
2017
21
Myeloperoxidase/HLA Class II Complexes Recognized by Autoantibodies in Microscopic Polyangiitis. ( 28575531 )
2017
22
Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis. ( 28569178 )
2017
23
Severe microscopic polyangiitis with unilateral vocal cord paralysis as initial manifestation. ( 28559644 )
2017
24
Not Every Case of Temporal Arteritis Is Giant Cell Arteritis. Microscopic Polyangiitis Involving the Temporal Artery: A Case Report and Review of the Literature. ( 29293114 )
2017
25
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis with Polyangiitis, Microscopic Polyangiitis or Polyarteritis Nodosa without Poor Prognosis Factors A Randomized-Controlled Trial. ( 28678392 )
2017
26
The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study. ( 28498830 )
2017
27
IgM Antibodies to Proteinase 3 in Granulomatosis with Polyangiitis and Microscopic Polyangiitis. ( 28076879 )
2017
28
Silicosis, then microscopic polyangiitis-antineutrophil cytoplasmic antibodies-associated vasculitis may be work-related disease in patients with silicosis. ( 29264045 )
2017
29
Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. ( 28422001 )
2017
30
Acute cervical myelitis and microscopic polyangiitis. ( 27158038 )
2016
31
Chronic and Asymptomatic Diffuse Alveolar Haemorrhage with Microscopic Polyangiitis: A Case Report and Review of the Literature. ( 28050304 )
2016
32
Very early renal relapse of microscopic polyangiitis after kidney transplantation. ( 27118023 )
2016
33
Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. ( 26934300 )
2016
34
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
35
Presence of Citrullinated Histone H3-Positive Neutrophils in Microscopic Polyangiitis from the Early Phase: An Autopsy Proven Case. ( 27427341 )
2016
36
Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study. ( 27400379 )
2016
37
Ultra-Wide-Field Fluorescein Angiography in Microscopic Polyangiitis. ( 27872779 )
2016
38
Microscopic polyangiitis complicated with bilateral brachial plexopathy: a case report and review of the literature. ( 26782370 )
2016
39
Successful Immunosuppressive Treatment of Mixed Connective Tissue Disease Complicated by Microscopic Polyangiitis. ( 27238624 )
2016
40
Protective Role of HLA-DRB1*13:02 against Microscopic Polyangiitis and MPO-ANCA-Positive Vasculitides in a Japanese Population: A Case-Control Study. ( 27166610 )
2016
41
Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients. ( 27169414 )
2016
42
Bilateral Scleritis and Retinal Vasculitis in Microscopic Polyangiitis. ( 27871395 )
2016
43
Diagnosis of perinuclear anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis in silicotics: case report. ( 27186376 )
2016
44
Microscopic polyangiitis with crescentic glomerulonephritis initially presenting as acute pancreatitis. ( 26864299 )
2016
45
[Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis]. ( 26346417 )
2016
46
Central nervous system vasculitis in pediatric microscopic polyangiitis: A case report and review of literature. ( 27156236 )
2016
47
Development of intracerebral hemorrhage in the short-term clinical course of a patient with microscopic polyangiitis without neurological symptoms at diagnosis: an autopsy case. ( 28508972 )
2016
48
Comparing presenting clinical features of 48 children with microscopic polyangiitis (MPA) against 183 having granulomatosis with polyangiitis (GPA). An ARChiVe study. ( 27111558 )
2016
49
Myeloperoxidase anti-neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis. ( 26833773 )
2016
50
Microscopic polyangiitis presenting with multiple punched-out ulcers: A case report. ( 27177686 )
2016

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

Pathways related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 HLA-B HLA-DRB1 IL10 KIR3DL1 MPO TNF
2
Show member pathways
13.03 HLA-B HLA-DRB1 IL10 TNF
3
Show member pathways
12.34 HLA-DRB1 IL10 TNF
4
Show member pathways
12.29 HLA-DRB1 IL10 TNF
5
Show member pathways
12.28 IL10 MPO TNF
6 12.25 IL10 MPO TNF
7
Show member pathways
12.2 HLA-B KIR3DL1 TNF
8 12.08 HLA-B HLA-DRB1 TNF
9 11.94 HLA-B HLA-DRB1 IL10
10
Show member pathways
11.88 HLA-DRB1 IL10 TNF
11 11.83 HLA-DRB1 IL10 TNF
12
Show member pathways
11.76 HLA-B HLA-DRB1 IL10 KIR3DL1 TNF
13 11.68 HLA-B HLA-DRB1 MPO
14
Show member pathways
11.64 HLA-B IL10 TNF
15 11.44 IL10 TNF
16 11.4 IL10 MPO TNF
17 11.35 HLA-DRB1 IL10
18 11.29 IL10 TNF
19 11.28 IL10 TNF
20 11.27 MPO TNF
21
Show member pathways
11.09 IL10 TNF
22 11.07 IL10 TNF
23 11.05 IL10 TNF
24 10.61 HLA-DRB1 IL10 TNF
25 10.57 MPO TNF

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 8.96 HLA-B HLA-DRB1
2 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.62 HLA-B HLA-DRB1

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.61 IL10 MPO TNF
2 interferon-gamma-mediated signaling pathway GO:0060333 9.56 HLA-B HLA-DRB1
3 response to glucocorticoid GO:0051384 9.55 IL10 TNF
4 antigen processing and presentation GO:0019882 9.54 HLA-B HLA-DRB1
5 negative regulation of T cell proliferation GO:0042130 9.52 HLA-DRB1 IL10
6 negative regulation of mitotic cell cycle GO:0045930 9.51 IL10 TNF
7 positive regulation of cytokine secretion GO:0050715 9.49 IL10 TNF
8 negative regulation of interferon-gamma production GO:0032689 9.48 HLA-DRB1 IL10
9 negative regulation of interleukin-6 production GO:0032715 9.46 IL10 TNF
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.4 IL10 TNF
11 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.37 IL10 TNF
12 immune response GO:0006955 9.35 HLA-B HLA-DRB1 IL10 KIR3DL1 TNF
13 endothelial cell apoptotic process GO:0072577 9.32 IL10 TNF
14 negative regulation of cytokine secretion involved in immune response GO:0002740 9.26 IL10 TNF
15 receptor biosynthetic process GO:0032800 9.16 IL10 TNF
16 negative regulation of growth of symbiont in host GO:0044130 8.8 IL10 MPO TNF

Molecular functions related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.62 HLA-B HLA-DRB1

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....